pazopanib pazopanib pazopanib, sold under the brand name votrient, is an anti-cancer medication marketed worldwide by novartis. it is a potent and selective multi-targeted receptor tyrosine kinase inhibitor that blocks tumour growth and inhibits angiogenesis. it has been approved for renal cell carcinoma and soft tissue sarcoma by numerous regulatory administrations worldwide. pazopanibclinical datapronunciation/pæˈzoʊpənɪb/ paz-oh-pə-nib trade namesvotrientahfs/drugs.commonographmedlineplusa610013license data eu ema: by inn us dailymed: pazopanib us fda: pazopanib pregnancycategory au: d routes ofadministrationby mouth (tablets)atc codel01ex03 (who) legal statuslegal status au: s4 (prescription only) ca: ℞-only uk: pom (prescription only) us: ℞-only eu: rx-only pharmacokinetic databioavailability21% (14–39%)protein binding>99.5%metabolismliver: cyp3a4 (major), 1a2 and 2c8 (minor)elimination half-life30.9±4 hoursexcretionfaeces (primary), urine (<4%)identifiers iupac name 5-(amino)-2-methylbenzenesulfonamide cas number444731-52-6 nas hcl: 635702-64-6 ypubchem cid11525740iuphar/bps5698drugbankdb06589 nchemspider9700526 yunii7rn5dr86ckas hcl: 33y9anm545 ykeggd05380 nchebichebi:71219 nchemblchembl477772 ncomptox dashboard (epa)dtxsid8048733 chemical and physical dataformulac21h23n7o2smolar mass437.52 g·mol−13d model (jsmol)interactive image smiles o=s(=o)(n)c1c(ccc(c1)nc2nccc(n2)n(c4ccc3c(nn(c3c)c)c4)c)c inchi inchi=1s/c21h23n7o2s.clh/c1-13-5-6-15(11-19(13)31(22,29)30)24-21-23-10-9-20(25-21)27(3)16-7-8-17-14(2)28(4)26-18(17)12-16;/h5-12h,1-4h3,(h2,22,29,30)(h,23,24,25);1h ykey:mqhiqubxffaomk-uhfffaoysa-n y ny (what is this?) (verify) medical uses it is approved by numerous regulatory administrations worldwide, including the us food and drug administration (fda) (19 october 2009), the european union's european medicines agency (ema) (14 june 2010), the united kingdom's medicines and healthcare products regulatory agency (mhra) (14 june 2010) and australia's therapeutic goods administration (tga) (30 june 2010), for use as a treatment for advanced/metastatic renal cell carcinoma and advanced soft tissue sarcomas. in australia and new zealand, it is subsidised under the pharmaceutical benefits scheme (pbs) and by pharmac respectively, under a number of conditions, including: the medication is used to treat clear cell renal cell carcinoma, the most common histological subtype. the treatment phase is continuing treatment beyond 3 months. the patient has been issued an authority prescription for pazopanib. the patient must have stable or responding disease according to the response evaluation criteria in solid tumours (recist). this treatment must be the sole tyrosine kinase inhibitor subsidised for this condition. pazopanib has also demonstrated initial therapeutic properties in patients with ovarian and non-small cell lung cancer, though plans to apply to the ema for a variation to include advanced ovarian cancer have been withdrawn and a license will not be sought in any country. contraindications the only contraindication is hypersensitivity to pazopanib or any of its excipients. cautions include: hypertension, including hypertensive crises have been reported. qt interval prolongation and torsades de pointes have been reported. thrombotic microangiopathy has been reported. thrombotic thrombocytopenic purpura has been reported. haemolytic uremic syndrome has been reported. haematologic parameter alterations have been reported in 31–37% of patients. events of cardiac dysfunction (decreased left ventricular ejection fraction and congestive heart failure) have been observed. fatal haemorrhage, arterial and venous thrombotic events and perforations in the gastrointestinal tract have been observed in randomized clinical trials. it has one black box warning by the us fda, namely severe hepatotoxicity including fatalities. adverse effects